Ibrutinib (PCI-32765, Imbruvica), the first Food and Drug Administration (FDA)-approved covalent irreversible BTK inhibitor, has been used successfully for the treatment of patients with relapsed or refractory mantle-cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Here, BTK is linked to mantle cell lymphoma.